Monograph Details
|
|
Infections & Infestations
> Fungal infections
|
|
LAMISIL TABLETS |
| Manufacturer |
|
Novartis Pharmaceuticals Corp |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Allylamine. |
| Generic Name |
|
Terbinafine (as HCl) 250mg. |
| Also |
|
• LAMISIL ORAL GRANULES
|
| Indications |
|
Onychomycosis of the toenail or fingernail due to tinea unguium. |
| Children |
|
<18 years: not recommended. |
| Adults |
|
≥18 years: 250mg once daily for 6 weeks (fingernail) or 12 weeks (toenail). |
| Precautions |
|
Onychomycosis: confirm diagnosis with nail specimen. Do baseline liver function test. Pre-existing hepatic disease or renal impairment (CrCl <50mL/min): not recommended. Discontinue if hepatobiliary dysfunction, progressive skin rash (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis), or severe neutropenia occurs. Monitor CBCs if immunodeficient. Pregnancy (Cat.B), nursing mothers: not recommended. |
| Interactions |
|
Potentiated by cimetidine. Antagonized by rifampin. May potentiate drugs metabolized by CYP2D6. May be potentiated by CYP2C9 and CYP3A4 inhibitors (eg, fluconazole, ketoconazole, amiodarone). Monitor cyclosporine. |
| Adverse Reactions |
|
GI disturbances, liver test abnormalities, rash, pruritus, taste disturbances, urticaria; also children: nasopharyngitis, headache, pyrexia, cough, upper respiratory infection; rare: hepatotoxicity, liver failure, lupus erythematosus. |
| How Supplied |
Tabs—30, 100
Packets—14, 42 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
